

Sample	Date	TKI/Treatment	BCR-ABL1/ABL1%	Mutations by SS	Mutations by DS	Compound
ALL-1	26/06/2013	DIAGNOSIS	111,09	WT	WT	
ALL-2	02/09/2013	DASATINIB at140 mg/daily (day 52)	1.22	WT	T315I (act>att) 0.56% T315I (act>atc) 1.44%	
ALL-3	25/09/2013	DASATINIB at140 mg/daily (day 85)	39.15	T315I (act>att) ~60%	T315I (act>att) 82.17% T315I (act>atc) 15.49%	
ALL-4	18/10/2013	POST – CHEMO Clofarabine (80 mg/daily. for 5 days) Cyclophosphamide (800 mg/daily. for 5 days)	1.69	T315I (act>att) 100%	T315I (act>att) 100%	
ALL-5	30/10/2013	BLINATUMOMAB (CD19 antibody)	0.03	WT	WT	
ALL-6	11/12/2013	POST 1st COURSE BLINATUMOMAB	0.008	WT	WT	
ALL-7	14/01/2014	2nd COURSE BLINATUMOMAB	116.82	T315I (act>att) ~60%	T315I (act>att) 79.91% T315I (act>atc) 7.06%	
ALL-8	05/02/2014	PONATINIB 45 mg/daily (day 21)	7.93	T315?	T315I (act>att) 58% T315I (act>atc) 47.14%	
ALL-9	16/04/2014	TRANSPLANT (day 30)	0.48	WT	T315I (act>att) 1.27% T315I (act>atc) 0.77%	
ALL-10	03/06/2014	TRANSPLANT (day 76)	65.3	T315I (act>att) ~80% F359V (ttc>gtc) ~20%	T315I (act>att) 44% T315I (act>atc) 9.16% F359V (ttc>gtc) 16.34% H396R (cat>cgt) 9.47%	T315I (act>att) + F359V 16.34% T315I (act>att) + H396R 9.47%
ALL-11	29/07/2014	CYTOREDUCTIVE CHEMOTHERAPY	87.7	T315? Y253H (tac>cac) ~20%	T315I (act>att) 17.93% T315I (act>atc) 67% Y253H (tac>cac) 5.05% F359V (ttc>gtc) 3.17% H396R (cat>cgt) 0.73%	T315I (act>atc) + Y253H 3.98% T315I (act>att)+ F359V 0.67%